How common is rhabdomyolysis in patients receiving lipid-lowering therapy?
Phillips
Paul S
PS
Interventional Cardiology and Cardiology Research at Scripps Mercy Hospital, San Diego, CA 92103, USA. Phillips.Paul@scrippshealth.org
D000368:Aged; D000924:Anticholesteremic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000069059:Atorvastatin; D015415:Biomarkers / Q000097:blood; D003402:Creatine Kinase / Q000097:blood; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006538:Heptanoic Acids / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D015994:Incidence; D008875:Middle Aged; D017035:Pravastatin / Q000009:adverse effects / Q000627:therapeutic use; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies; D012206:Rhabdomyolysis / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology*; D012307:Risk Factors; D019821:Simvastatin / Q000009:adverse effects / Q000627:therapeutic use; D014481:United States / Q000453:epidemiology
D000924:Anticholesteremic Agents; D015415:Biomarkers; D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin; D019821:Simvastatin; D003402:Creatine Kinase; D017035:Pravastatin